

Review Article

Glaucoma in Iridocorneal Endothelial Syndrome: A Brief Review

Maryam Yadgari ^{1,2,*}, MD

1. Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2. Department of Ophthalmology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

***Corresponding Author:** Maryam Yadgari

E-mail: maryam.yadgari@yahoo.ie

Abstract

The iridocorneal endothelial (ICE) syndrome is a sporadic corneal endothelial disease that causes corneal endothelial cell abnormality as epithelialization, resulting in intractable glaucoma and corneal decompensation, often needing glaucoma surgery and corneal transplantation without a good prognosis. The most effective way to diagnose early is in-vivo confocal microscopy. Early treatment, especially for resultant glaucoma, improves diagnosis.

Keywords: Glaucoma; Iridocorneal Endothelial Syndrome; Intraocular Pressure.

Article Notes: Received: Jul. 03, 2021; Received in revised form: Aug. 13, 2021; Accepted: Sep. 29, 2021; Available Online: Jan. 01, 2022.

How to cite this article: Yadgari M. Glaucoma in Iridocorneal Endothelial Syndrome: A Brief Review. Journal of Ophthalmic and Optometric Sciences . 2022;6(1):

Introduction

The iridocorneal endothelial (ICE) syndrome is typically unilateral ¹ (in more than 90 % of cases), ² non-familial, progressive spectrum of proliferative abnormal corneal endothelial cells present in the iris stroma and anterior chamber angle ^{1, 3-5}.

This spectrum includes essential iris atrophy as predominant iris stromal atrophy causing corectopia, polycoria, and peripheral anterior synechiae, Chandler syndrome with severe corneal endothelial involvement causing a “hammered-silver” or “beaten-bronze” appearance ^{6, 7} and corneal edema, with the least amount of iris abnormality, and iris nevus / Cogan-Reese syndrome causing iris nevus or nodules ^{1, 4, 8-13}. Chandler syndrome is the most common variant in Whites, but the Cogan-Reese syndrome is more frequent in Asians ^{1, 7, 14}.

It typically manifests in white young or middle-aged adults in the third to fifth decade of their lives ^{1, 15, 16}, with a female predilection ^{10, 17-22}, but there are some reports of this abnormality in childhood age ²³⁻²⁷. The major complications of ICE syndrome are glaucoma and corneal edema. Glaucoma arises from changed endothelial cells. Epithelialization of them leads to secondary open and angle closure glaucoma with proliferation and migration of endothelial cells over the angle, resulting in peripheral anterior synechiae. The corneal edema in ICE syndrome is secondary to elevated intraocular pressure (IOP) and subnormal pump function of diseased corneal endothelial cells ²⁸.

Pathophysiology

The major pathology is in diseased corneal endothelial cells called ICE-cells with a tendency to divide, mitosis, and develop into multiple endothelial layers ²⁹⁻³²; sometimes,

there are called subtotal ICE, so diseased and normal endothelial cells are adjacent to each other in a transmission zone called a boundary zone with non-motile but high metabolic activity ³¹. Similar to ex-vivo, in-situ characteristics are mentioned in multiple studies ^{16, 31, 33-35}. Proliferation, contraction, and migration of diseased endothelial cells across the angle and on the iris. This results in corneal decompensation, collapsed trabecular beams, decreased intertrabecular spaces, and synechiae formation resulting in secondary open angle or angle closure glaucoma ^{6, 7, 20}. Another change in the corneal endothelial cells is contraction causing iris atrophy, thinning of iris stroma, and full-thickness holes’ formation are named stretch holes and ectropion uvea, polycoria, and corectopia ^{12, 22, 23, 29, 36}.

The diseased endothelial cells acquire an epithelial-like pattern prominently on the apical surface, owning desmosomes, filopodia and microvilli, vimentin, blebs, and cytokeratin ³⁷⁻³⁹.

Its etiology is unclear ^{1, 3-7}, but some evidence supports the viral origin, such as the existence of inflammatory cells on histological evaluation ⁴⁰. Herpes simplex virus or Epstein Barr virus is proposed as the primary etiology of this disease ^{11, 36, 41-43} by the integration of viral genetic material into the human genome ^{3, 37}, resulting in necrotic events ³³.

There are some reports of accompanying other ocular diseases such as microspherophakia ¹¹ and keratoconus ^{37, 39, 44-47}, macular edema ⁴⁸⁻⁵⁰, retinal neurosensory detachment ⁴⁷, and also systemic diseases such as Downs syndrome ²³.

Diagnosis

Patients typically perceive predominantly morning visual haze, leading to decreased visual acuity and halos due to corneal edema. Some patients prefer changes in the shape or

position of the pupils ⁵¹.

Subclinical corneal abnormalities are not uncommon in the fellow eye ^{18, 19} and bilateral clinical ICE or are reported ^{23, 52, 53}. Specular or in-vivo corneal confocal microscopy is useful for diagnosis confirmation ⁷. Specular microscopy shows ICE-cells that are epithelial-like endothelial cells as large, rounded, and pleomorphic cells with polymegathism and also a typical “light-dark reverse” as a dark surface with light spots at the central area (hyperreflective nuclei) and also a light border between cells ^{6, 20, 34, 54}.

In-vivo confocal microscopy is over specular microscopy because of higher resolution, image contrast, and the ability to image all corneal cellular layers. It is less affected by corneal pathologies such as edema or mild scarring ³³.

Confocal microscopy shows two patterns of diseased endothelial changes in ICE syndrome. The first type is small cells with indistinct borders and bright, prominent, uniform nuclei. The second type is larger, epithelial-like cells with irregular borders and non-homogenous, diversely shaped nuclei, but increased reflectivity of the intercellular spaces is seen in nearly all cases ⁵⁵.

In confocal microscopy, there are two types of ICE cells: ICE minus variant of endothelial cells (large cells with widely spaced centrally placed hyperreflective nuclei) or ICE plus variant of diseased endothelial cells (smaller cells with more tightly packed, eccentrically placed hyperreflective nuclei) without any effect of prognostic effect but more minus type in males ². Corneal confocal microscopy, with its high magnification, also detects ICE cells ^{2, 33, 55, 56}, so confocal microscopy could provide good evidence for early diagnosis of ICE syndrome, especially for differentiation of ICE mimickers such as Fuchs endothelial

dystrophy ⁵⁶.

Ultrasound biomicroscopy (UBM) may be useful for detecting anterior chamber angle changes in corneal edema that make gonioscopy impossible ^{6, 51}.

The two major vision-threatening sequelae of ICE syndrome are glaucoma and corneal decompensation. The severity of the disease and the predominant clinical variants differ among various ethnicities ^{1, 10, 57}. Chandran et al. reported secondary glaucoma in 73 % of the ICE cases. 50 % of them endured refractory glaucoma and were scheduled for glaucoma surgery. They also found corneal edema in 56 % of ICE syndromes, and 14 % of these cases needed corneal transplantation ⁹. The differential diagnosis of the ICE syndrome is Fuchs endothelial dystrophy and Posterior polymorphous corneal dystrophy ^{15, 56}.

Treatment

In recent years, there have been some advancements in the treatment of ICE syndrome, and new references have emerged. Currently, there is still no preventative method for the disease, and patients are typically monitored until they develop increased intraocular pressure or corneal decompensation ²⁵. The treatment focuses on managing the two major complications of the disease, corneal edema, and glaucomatous optic neuropathy.

Medical management remains the first choice of treatment for ICE syndrome, similar to other types of glaucoma. However, antiglaucomatous medications have limited effects on the disease due to its refractory nature, and medical therapy may have some limitations in these patients. For example, dorzolamide usage may lead to deterioration in the endothelial cell function ⁵⁸⁻⁶¹, and latanoprost has been associated with herpes simplex recurrence, which may interfere with

the ICE syndrome⁴¹. Therefore, the rate of IOP control failure with topical antiglaucoma medications is high, ranging from 60-80 %⁵¹. Surgical intervention is often necessary for patients with ICE syndrome. Trabeculectomy has been used to treat the disease, but it results in a lower success rate than shunt procedures. The success rate of trabeculectomy ranges from 60-73 % at one year, approximately 40 % two years after surgery, and 21-29 % five years after surgery^{5, 62-64}. Even after re-trabeculectomy, the success rate may still be low, with 20 % of cases requiring a second surgery⁶³. The ingrowth of diseased endothelial cells in the filtration site may contribute to this failure⁴. In cases where trabeculectomy fails, glaucoma drainage devices may be required, with success rates ranging from 50-53 % after five years of follow-up^{64, 65}.

Cyclo-destructive procedures have been found to be more effective than other types of glaucoma treatments for controlling IOP in ICE syndrome, especially considering the age of patients. However, due to the ingrowth of diseased endothelial cells, deep sclerectomy is contraindicated in ICE syndrome⁶⁶.

Hypertonic solutions may provide temporary relief of morning visual blurring, but eventually, patients may need corneal transplantation, such as Descemet membrane endothelial keratoplasty or Descemet's stripping automated endothelial keratoplasty. However, DSAEK can be challenging in patients with ICE syndrome and peripheral anterior synechiae (PAS) due to the shallow anterior chamber and iris abnormalities that may make it harder for the donor tissue to unfold correctly^{15, 67-73}.

Recent studies have investigated new treatment options for ICE syndrome, including the use of selective laser trabeculoplasty (SLT) and gonioscopy-assisted transluminal

trabeculotomy (GATT). SLT has shown promising results in reducing IOP in patients with ICE syndrome, with one study reporting a mean IOP reduction of 20.8 % after six months⁷⁴. GATT, a minimally invasive surgical technique, has also shown promise in reducing IOP in patients with ICE syndrome, with one study reporting a mean IOP reduction of 52.8 % after six months⁷⁵. Another study reported successful outcomes with the use of a microinvasive glaucoma surgery device called the Kahook Dual Blade in patients with ICE syndrome⁷⁶. These new treatment options may provide additional options for managing IOP in patients with ICE syndrome and may help reduce the need for more invasive surgical interventions.

In summary, while there is no preventative method for ICE syndrome, medical management and surgical intervention can help manage the disease's complications. Despite its refractory nature, treatment options such as cyclo-destructive procedures and glaucoma drainage devices may be effective for controlling IOP. In cases where corneal transplantation is necessary, DSAEK can be challenging but remains a viable option for patients.

Conclusion: In conclusion, ICE syndrome is a rare disorder that can lead to significant vision loss and glaucomatous optic neuropathy. Despite the refractory nature of the disease, early diagnosis and careful management are crucial for a better prognosis. While medical management is the first choice of treatment, it may have limited effects due to the endothelial cell abnormalities present in ICE syndrome. Surgical options, including trabeculectomy, glaucoma drainage devices, and newer techniques such as selective laser trabeculoplasty and gonioscopy-assisted transluminal trabeculotomy, have shown

promising results in reducing IOP in patients with ICE syndrome. Additionally, careful consideration of the challenges associated with corneal transplantation techniques may be necessary. Close follow-up and monitoring are critical in the management of ICE syndrome to prevent catastrophic consequences and preserve vision.

Authors ORCIDs

Maryam Yadgari:

 <https://orcid.org/0000-0003-0829-1861>

References:

1. Shields MB. Progressive essential iris atrophy, Chandler's syndrome, and the iris nevus (Cogan-Reese) syndrome: a spectrum of disease. *Survey of ophthalmology*. 1979;24(1):3-20.
2. Malhotra C, Seth NG, Pandav SS, Jain AK, Kaushik S, Gupta A, et al. Iridocorneal endothelial syndrome: Evaluation of patient demographics and endothelial morphology by in vivo confocal microscopy in an Indian cohort. *Indian Journal of Ophthalmology*. 2019;67(5):604.
3. Li F, Liu Y, Sun Y, Zhang X. Etiological mechanism of iridocorneal endothelial (ICE) syndrome may involve infection of herpes simplex virus (HSV) and integration of viral genes into human genome. *Medical hypotheses*. 2018;110:50-2.
4. Eagle RC, Font RL, Yanoff M, Fine BS. Proliferative endotheliopathy with iris abnormalities: the iridocorneal endothelial syndrome. *Archives of Ophthalmology*. 1979;97(11):2104-11.
5. Laganowski HC, Muir MGK, Hitchings RA. Glaucoma and the iridocorneal endothelial syndrome. *Archives of Ophthalmology*. 1992;110(3):346-50.
6. Sacchetti M, Mantelli F, Marengo M, Macchi I, Ambrosio O, Rama P. Diagnosis and management of iridocorneal endothelial syndrome. *BioMed research international*. 2015;2015.
7. Silva L, Najafi A, Suwan Y, Teekhasaene C, Ritch R. The iridocorneal endothelial syndrome. *survey of ophthalmology*. 2018;63(5):665-76.
8. Yanoff M. Iridocorneal endothelial syndrome: unification of a disease spectrum. 1979.
9. Chandran P, Rao HL, Mandal AK, Choudhari NS, Garudadri CS, Senthil S. Glaucoma associated with iridocorneal endothelial syndrome in 203 Indian subjects. *PLoS One*. 2017;12(3):e0171884.
10. Wilson MC, Shields MB. A comparison of the clinical variations of the iridocorneal endothelial syndrome. *Archives of ophthalmology*. 1989;107(10):1465-8.
11. Islam F, Azad N, Khan A. Bilateral iridocorneal endothelial (ICE) syndrome with microspherophakia. *J Coll Physicians Surg Pak*. 2011;21(6):374e5.
12. Campbell DG, Shields MB, Smith TR. The corneal endothelium and the spectrum of essential iris atrophy. *American journal of ophthalmology*. 1978;86(3):317-24.
13. Aihara M. Glaucoma and iridocorneal endothelial (ICE) syndrome. *Ophthalmology*. 2008;50(1420):1.
14. Shields MB, Campbell DG, Simmons RJ, Hutchinson BT. Iris nodules in essential iris atrophy. *Archives of Ophthalmology*. 1976;94(3):406-10.
15. Sorkin N, Einan-Lifshitz A, Boutin T, Showail M, Borovik A, Chan CC, et al. Descemet membrane endothelial keratoplasty in iridocorneal endothelial syndrome and posterior polymorphous corneal dystrophy. *Canadian Journal of Ophthalmology*.

- 2019;54(2):190-5.
16. Levy S, Kirkness C, Moss J, Ficker L, McCartney A. The histopathology of the iridocorneal-endothelial syndrome. *Cornea*. 1996;15(1):46-54.
17. Shields MB, Campbell DG, Simmons RJ. The essential iris atrophies. *American journal of ophthalmology*. 1978;85(6):749-59.
18. Hemady RK, Patel A, Blum S, Nirankari VS. Bilateral iridocorneal endothelial syndrome: case report and review of the literature. *Cornea*. 1994;13(4):368-72.
19. Huna R, Barak A, Melamed S. Bilateral iridocorneal endothelial syndrome presented as Cogan-Reese and Chandler's syndrome. *Journal of glaucoma*. 1996;5(1):60-2.
20. Hirst LW, Qulgley HA, Stark WJ, Shields NB. Specular microscopy of iridocorneal endothelial syndrome. *Australian Journal of Ophthalmology*. 1980;8(2):139-46.
21. Liu Y-K, Wang I-J, Hu F-R, Hung T, Chang H-W. Clinical and specular microscopic manifestations of iridocorneal endothelial syndrome. *Japanese journal of ophthalmology*. 2001;45(3):281-7.
22. Le Q-H, Sun X-H, Xu J-J. In-vivo confocal microscopy of iridocorneal endothelial syndrome. *International ophthalmology*. 2009;29(1):11-8.
23. Gupta V, Kumar R, Gupta R, Srinivasan G, Sihota R. Bilateral iridocorneal endothelial syndrome in a young girl with Down's syndrome. *Indian Journal of Ophthalmology*. 2009;57(1):61.
24. Tang W, Wang Q, Zhang Q, Sun S, Zhang Y, Wu Z. Iridocorneal endothelial syndrome in a Chinese child. *Eye Science*. 2013;28(3):153-6.
25. Aponte EP, Ball DC, Alward WL. Iridocorneal endothelial syndrome in a 14-year-old male. *Journal of Glaucoma*. 2016;25(2):e115-e6.
26. Salim S, Shields MB, Walton D. Iridocorneal endothelial syndrome in a child. *Journal of Pediatric Ophthalmology and Strabismus*. 2006;43(5):308.
27. Olawoye O, Teng CC, Liebmann JM, Wang FM, Ritch R. Iridocorneal endothelial syndrome in a 16-year-old. *Journal of Glaucoma*. 2011;20(5):294-7.
28. Weisenthal R, Daly M, Feder R, Orlin S, Tu E, Van Meter W. Clinical approach to depositions and degenerations of the conjunctiva, cornea, and sclera. *Basic and Clinical Science Course (BCSC)*. 2017;2018:111-2.
29. Krasieńska A, Mamczur J, Pajdowska M, Bążert A. Difficulties in treatment of iridocorneal endothelial syndrome-case report. *Medical Journal of Cell Biology*. 10(2):56-60.
30. Levy SG, McCartney A, Baghai MH, Barrett MC, Moss J. Pathology of the iridocorneal-endothelial syndrome. The ICE-cell. *Investigative ophthalmology & visual science*. 1995;36(13):2592-601.
31. Levy S, Kirkness C, Moss J, Ficker L, McCartney A. On the pathology of the iridocorneal-endothelial syndrome: the ultrastructural appearances of 'subtotal-ice'. *Eye*. 1995;9(3):318-23.
32. Li S, Sun B, Zheng Q, Ren Y, Zhao Z, Wang H, et al. Clinical outcomes of the intraocular lens injector for Descemet stripping automated endothelial keratoplasty in patients with iridocorneal endothelial syndrome. 2022.
33. Chiou AG, Kaufman SC, Beuerman RW, Ohta T, Yaylali V, Kaufman HE. Confocal microscopy in the iridocorneal endothelial syndrome. *British journal of ophthalmology*. 1999;83(6):697-702.
34. Sherrard ES, Frangoulis MA, Muir M. On the morphology of cells of posterior cornea in the iridocorneal endothelial syndrome. *Cornea*. 1991;10(3):233-43.
35. Kupfer C, Kaiser-Kupfer MI, Datiles

- M, McCain L. The contralateral eye in the iridocorneal endothelial (ICE) syndrome. *Ophthalmology*. 1983;90(11):1343-50.
36. Denis P. Iridocorneal endothelial syndrome and glaucoma. *Journal Francais D'ophtalmologie*. 2007;30(2):189-95.
37. Li Y, McLintock C, Lake D, McKelvie J. Coincident iridocorneal endothelial syndrome and keratoconus. *Indian Journal of Ophthalmology-Case Reports*. 2021;1(2):234.
38. Hirst LW, Green WR, Luckenbach M, de la Cruz Z, Stark WJ. Epithelial characteristics of the endothelium in Chandler's syndrome. *Investigative Ophthalmology & Visual Science*. 1983;24(5):603-11.
39. Hirst LW, Bancroft J, Yamauchi K, Green WR. Immunohistochemical pathology of the corneal endothelium in iridocorneal endothelial syndrome. *Investigative ophthalmology & visual science*. 1995;36(5):820-7.
40. Praveena G, Medikonda M, Mashru N. Cogan-Reese syndrome: A variant of iridocorneal endothelial syndrome. *The Official Scientific Journal of Delhi Ophthalmological Society*. 2018;28(4):72-4.
41. Alvarado JA, Underwood JL, Green WR, Wu S, Murphy CG, Hwang DG, et al. Detection of herpes simplex viral DNA in the iridocorneal endothelial syndrome. *Archives of Ophthalmology*. 1994;112(12):1601-9.
42. Groh M, Seitz B, Schumacher S, Naumann G. Detection of herpes simplex virus in aqueous humor in iridocorneal endothelial (ICE) syndrome. *Cornea*. 1999;18(3):359-60.
43. Rasquinha M. Irido-corneal endothelial syndrome: an overview.
44. De Maria M, Iannetta D, Moramarco A, Fontana L. Iridocorneal endothelial syndrome in a patient with keratoconus—a case report. *BMC ophthalmology*. 2019;19(1):1-6.
45. Gus PI, Araújo BSd, Zelanis S, Schmalfuss TR, Marinho DR. Posterior keratoconus and iris atrophy: a fortuitous association? *Arquivos Brasileiros de Oftalmologia*. 2019;82:68-71.
46. Chakrabarty L. A unique case of keratoconus with Cogan-Reese syndrome and secondary glaucoma. *Indian Journal of Ophthalmology*. 2017;65(1):64.
47. Dubey S, Jain K, Singh S, Mukhejee S. Iridocorneal Endothelial Syndrome with Coexisting Macular Edema and Neurosensory Detachment: An Unusual Case Report. *Journal of Current Glaucoma Practice*. 2021;15(3):149.
48. Kocaoglan H, Ünlü N, Kanpolat A, Yalvaç IS, Acar MA, Duman S. Macular edema and iridocorneal endothelial syndrome: a case report. *Cornea*. 2005;24(2):221-3.
49. Fourmaux E, Velasque L. Progressive essential iris atrophy associated with chronic cystoid macular edema. *Journal Francais D'ophtalmologie*. 2005;28(4):407-10.
50. Suzuki K, Mizuguchi T, Seno Y, Tanikawa A, Horiguchi M. Cystoid macular edema associated with iridocorneal endothelial syndrome: a case report. *BMC ophthalmology*. 2016;16(1):1-4.
51. Estacia CT, Gameiro AR, Faccenda PG, Negri RV, Chianello DT, Alves MAS. Iridocorneal Endothelial Syndrome: Case Report of Chandler's Variant. *Revista Brasileira De Oftalmologia*. 2017;76:207-9.
52. Merca TGB, Agulto MB, Covar RVA. Bilateral Iridocorneal Endothelial Syndrome. *Philippine Journal of Ophthalmology*. 2022;47(2).
53. Farrah I, Nadia A, Ayesha K. Bilateral iridocorneal endothelial [ICE] syndrome with microspherophakia. 2011.
54. Sherrard E, Frangoulis M, Muir M, Buckley R. The posterior surface of the cornea in the irido-corneal endothelial syndrome: a specular microscopical study. *Transactions of the Ophthalmological Societies of the United Kingdom*. 1985;104:766-74.

55. Grupcheva CN, McGhee CN, Dean S, Craig JP. In vivo confocal microscopic characteristics of iridocorneal endothelial syndrome. *Clinical & experimental ophthalmology*. 2004;32(3):275-83.
56. Sheppard Jr JD, Lattanzio Jr FA, Williams PB, Mitrev PV, Allen RC. Confocal microscopy used as the definitive, early diagnostic method in Chandler syndrome. *Cornea*. 2005;24(2):227-9.
57. Teekhasaene C, Ritch R. Iridocorneal endothelial syndrome in Thai patients: clinical variations. *Archives of Ophthalmology*. 2000;118(2):187-92.
58. Fischbarg J, Lim J. Role of cations, anions and carbonic anhydrase in fluid transport across rabbit corneal endothelium. *The Journal of physiology*. 1974;241(3):647-75.
59. Malikowski TM, Bosch JB, Min S, Duffey ME, Patel SP. Carbonic anhydrase inhibitors in corneal endothelial transport. *Investigative Ophthalmology & Visual Science*. 2014;55(4):2652-8.
60. Wirtitsch MG, Findl O, Heinzl H, Drexler W. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. *Archives of Ophthalmology*. 2007;125(10):1345-50.
61. Konowal A, Morrison J, Brown S, Cooke D, Maguire L, Verdier D, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. *American journal of ophthalmology*. 1999;127(4):403-6.
62. Wilson CA, Choromokos EA, Sheppard R. Acute posterior multifocal placoid pigment epitheliopathy and cerebral vasculitis. *Archives of ophthalmology*. 1988;106(6):796-800.
63. Lanzl IM, Wilson RP, Dudley D, Augsburger JJ, Aslanides IM, Spaeth GL. Outcome of trabeculectomy with mitomycin-C in the iridocorneal endothelial syndrome. *Ophthalmology*. 2000;107(2):295-7.
64. Doe EA, Budenz DL, Gedde SJ, Imami NR. Long-term surgical outcomes of patients with glaucoma secondary to the iridocorneal endothelial syndrome. *Ophthalmology*. 2001;108(10):1789-95.
65. Kim DK, Aslanides IM, Schmidt Jr CM, Spaeth GL, Wilson RP, Augsburger JJ. Long-term outcome of aqueous shunt surgery in ten patients with iridocorneal endothelial syndrome. *Ophthalmology*. 1999;106(5):1030-4.
66. Sarodia U, Shaarawy T, Barton K. Nonpenetrating glaucoma surgery: a critical evaluation. *Current opinion in ophthalmology*. 2007;18(2):152-8.
67. Bahar I, Kaiserman I, Buys Y, Rootman D. Descemet's stripping with endothelial keratoplasty in iridocorneal endothelial syndrome. *Ophthalmic Surgery, Lasers and Imaging Retina*. 2008;39(1):54-6.
68. Quek DT-L, Wong CW, Wong TT, Han SB, Htoon HM, Ho CL, et al. Graft failure and intraocular pressure control after keratoplasty in iridocorneal endothelial syndrome. *American Journal of Ophthalmology*. 2015;160(3):422-9. e1.
69. Price MO, Price Jr FW. Descemet stripping with endothelial keratoplasty for treatment of iridocorneal endothelial syndrome. *Cornea*. 2007;26(4):493-7.
70. Bromley JG, Randleman JB, Stone D, Stulting RD, Grossniklaus HE. Clinicopathologic findings in iridocorneal endothelial syndrome and posterior polymorphous membranous dystrophy after Descemet stripping automated endothelial keratoplasty. *Cornea*. 2012;31(9):1060-4.
71. Melles GR, San Ong T, Ververs B, van der Wees J. Descemet membrane endothelial keratoplasty (DMEK). *Cornea*. 2006;25(8):987-90.

72. Gorovoy MS. Descemet-stripping automated endothelial keratoplasty. *Cornea*. 2021;40(3):270-3.
73. Tourtas T, Laaser K, Bachmann BO, Cursiefen C, Kruse FE. Descemet membrane endothelial keratoplasty versus descemet stripping automated endothelial keratoplasty. *American journal of ophthalmology*. 2012;153(6):1082-90. e2.
- 74 Razeghinejad MR, Hosseini H, Ahmadi F. Selective laser trabeculoplasty in ICE syndrome: a case series study. *Int Ophthalmol*. 2021;41(2):471-8.
- 75 Töteberg-Harms M, Katz LJ, Blieden LS. Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) in Patients With ICE Syndrome. *J Glaucoma*. 2020;29(9):824-8.
- 76 Takkar B, Tripathy K, Dhar D. Microinvasive Glaucoma Surgery in Iridocorneal Endothelial Syndrome. *J Glaucoma*. 2021;30(4):335-9.

Footnotes and Financial Disclosures

Conflict of interest:

The authors have no conflict of interest with the subject matter of the present manuscript.